» Articles » PMID: 35335981

In Vitro Biological Evaluation of Aprepitant Based Lu-Radioconjugates

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Mar 26
PMID 35335981
Authors
Affiliations
Soon will be listed here.
Abstract

Currently, the search for promising NK1R-positive tumor-targeting radiopharmaceuticals based on the structure of small molecular antagonists of neurokinin-1 receptor can be observed. Following this trend, we continued our evaluation of aprepitant-based Lu-radioconjugates in terms of future oncological applications. For this purpose, three novel aprepitant homologues were synthesized to broaden the previously obtained derivative portfolio, functionalized with the DOTA chelator and labeled with Ga and Lu. The newly evaluated radioconjugates showed the intended significant increase in lipophilicity compared to the previous ones, while maintaining stability in the human serum. Then, in a receptor binding study to the human NK1 receptor, we compared the two series of Lu-radioconjugates of aprepitant with each other and with the reference Substance P derivative currently used in glioblastoma therapy, clearly indicating the high affinity and better binding capacity of the novel radioconjugates. The in vitro experimental results included in the presented study, supported by labeling optimization, radioconjugate characterization and docking modeling of new aprepitant-derived radioagents, confirm our assumptions about the usefulness of aprepitant as a NK1R targeting vector and point out the perspectives for the forthcoming first in vivo trials.

Citing Articles

Radiotherapy Plus the Neurokinin-1 Receptor Antagonist Aprepitant: A Potent Therapeutic Strategy for the Treatment of Diffuse Intrinsic Pontine Glioma.

Munoz M, Rosso M Cancers (Basel). 2025; 17(3).

PMID: 39941886 PMC: 11816061. DOI: 10.3390/cancers17030520.


Glioma and Peptidergic Systems: Oncogenic and Anticancer Peptides.

Sanchez M, Mangas A, Covenas R Int J Mol Sci. 2024; 25(14).

PMID: 39063232 PMC: 11277022. DOI: 10.3390/ijms25147990.


Advances in the research and application of neurokinin-1 receptor antagonists.

Hong X, Ma J, Zheng S, Zhao G, Fu C J Zhejiang Univ Sci B. 2024; 25(2):91-105.

PMID: 38303494 PMC: 10835208. DOI: 10.1631/jzus.B2300455.


The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.

Covenas R, Rodriguez F, Robinson P, Munoz M Int J Mol Sci. 2023; 24(21).

PMID: 37958914 PMC: 10650658. DOI: 10.3390/ijms242115936.


Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance.

Garcia-Aranda M, Tellez T, McKenna L, Redondo M Cancers (Basel). 2022; 14(9).

PMID: 35565383 PMC: 9102068. DOI: 10.3390/cancers14092255.

References
1.
Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo E, Park S, Mayordomo C . Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 2013; 73(21):6424-34. DOI: 10.1158/0008-5472.CAN-12-4573. View

2.
Cordier D, Gerber A, Kluba C, Bauman A, Hutter G, Mindt T . Expression of different neurokinin-1 receptor (NK1R) isoforms in glioblastoma multiforme: potential implications for targeted therapy. Cancer Biother Radiopharm. 2014; 29(5):221-6. DOI: 10.1089/cbr.2013.1588. View

3.
Bossaller C, Reither K, Auch-Schwelk W, Graf K, Grafe M, Fleck E . In vivo measurement of endothelium-dependent vasodilation with substance P in man. Herz. 1992; 17(5):284-90. View

4.
Munoz M, Covenas R, Esteban F, Redondo M . The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci. 2015; 40(2):441-63. DOI: 10.1007/s12038-015-9530-8. View

5.
Munoz M, Covenas R . The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?. Cancers (Basel). 2020; 12(9). PMC: 7564414. DOI: 10.3390/cancers12092682. View